BIVF IN A NUTSHELL
Established in 2010, the Boehringer Ingelheim Venture Fund (BIVF) is a EUR 350M evergreen fund with a global presence in the EU, US, and China. BIVF is committed to advancing scientific innovation by investing in first-in-class, disease-modifying therapeutics across various modalities.

OUR EXPERTISE & FOCUS AREAS
As a dedicated Seed/Series A investor with company formation expertise we primarily invest in pre-clinical assets and platforms. Our investment focus is on ground-breaking innovation in Cancer (immuno-oncology & targeted therapy) Regenerative medicine (incl. cell reprogramming & neuro degeneration) Auto-immunity indications Digital solutions (supporting the pharma value chain) Infectious disease (focus to AMR) Our activities are closely aligned with Boehringer Ingelheim‘s strategic interests and promote fostering potential business development targets. We strategically take a minority shareholder position and require a voting board seat to actively support our portfolio companies.

Contact person

Detlev Mennerich
Global Head of BI Venture Fund

Capital under management
EUR 350M evergreen fund

Industry focus
As a early investor with company formation expertise, the Boehringer Ingelheim Venture Fund is committed to advancing scientific innovation by investing in first-in-class, disease-modifying therapeutics across various modalities.

Portfolio and exits
Portfolio (DACH only): Acousia, Abalos, Aignostics, Evla, Heparegenix, Quantro, Refoxy, Smartbax, Switchkine, TecRegen, Tacalyx, T-Knife & Topas.
Exits (DACH only): Amal, Cardior, Hookipa, ICD, NBE, Okairos, Rigontec, T3 Pharma & ViraT.

Our Long Term vision
Our Investment aim to redefine standards of care and drive Boehringer Ingelheim‘s expansion into groundbreaking medical treatments. We are shaping the future of healthcare by supporting the aforementioned transformative areas. Our strategic investments position BIVF as a leader in propelling innovation.

Our Achievements
With currently over 40 portfolio companies, incl. a limited number of strategic Fund-in-Fund investments, BIVF has successfully facilitated 14 exits, including 6 exits to Boehringer Ingelheim.

Date of foundation / Number of employees
2010 / 25

Contact details

Address: Binger Strasse 173 | 55216 Ingelheim am Rhein
E-Mail: venture@boehringer-ingelheim.com
Web Address: www.boehringer-ingelheim-venture.com

Others
for inquiries:
www.boehringer-ingelheim-venture.com/contact